abstract: PURPOSE: @entity10327 and @entity13695 encode @entity3899 lipoxygenases which produce lipid metabolites involved in inflammatory processes. Metabolites generated by @entity10327 and @entity13695 can activate the expression of the potent pro-inflammatory cytokine @entity650 , and produce endogenous ligands for @entity6864 . In this study, polymorphisms in @entity10327 , @entity13695 , @entity650 and @entity6864 were investigated for association with bone properties in young and elderly Swedish @entity1 . METHODS: Three SNPs in @entity10327 , five in @entity13695 , one each in @entity650 and @entity6864 were genotyped in the cohorts PEAK-25 (n=1061 @entity1 ; all 25y) and OPRA (n=1044 @entity1 ; all 75y). @entity79 ( @entity79 ) and quantitative ultrasound (QUS) were analyzed in both cohorts; @entity79 ( @entity79 ) in PEAK-25; @entity604 , @entity174 incidence and serum @entity1851 (CRP) were assessed in OPRA. RESULTS: In the elderly @entity1 @entity13695 ( @entity51698 ) was associated with CRP levels (p=0.004) and incident @entity174 of any type (p=0.014), although not with @entity79 or ultrasound. In young @entity1 , carrying the common T allele (ALOX 15 @entity70599 ) was associated with lower QUS values (p=0.002-0.006). The @entity650 SNP was associated with lower @entity79 in PEAK-25 (femoral neck p=0.034; hip p=0.012). @entity79 was not associated with variation in any gene. Variants in the @entity10327 and PPARy were not associated with @entity79 in either cohort. CONCLUSIONS: This study suggests that variation in @entity32 related genes @entity13695 and @entity650 was associated with bone microarchitecture and density in young adult @entity1 , but appears to be less important in the elderly, despite an observed association with CRP as a marker of @entity32 and incident @entity174 .

title: Polymorphisms in @entity32 associated genes @entity13695 and @entity650 are associated with bone properties in young XXXX and @entity174 in elderly.

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND: Over the past decade, the National Action program @entity6 (NAD) was implemented in the Netherlands. Its aim was to introduce the Care Standard (CS) for @entity6 by means of a specific implementation plan and piloting in several regions. This study aimed to provide insight into the implementation of the NAD as, coupled with the introduction of the CS, it may function as an example for similar approaches in other countries. METHODS: A series of quantitative studies ( @entity1 2010: N   =   1726, @entity1 2013: N   =   1370 _ @entity1 pilot regions 2013: N   =   168) and qualitative studies ( @entity1 2010: N   =   18 and @entity1 2013: N   =   4) was conducted among @entity283 ( @entity283 ). In addition, two quantitative studies were conducted among type 1 and 2 @entity1 ( @entity1 2010: N   =   573; @entity1 2013: N   =   5056). RESULTS: Overall, positive changes in @entity6 care were detected in the period 2010 - 2013. In 2013 significantly more @entity283 were familiar with the CS (43.7 versus 37.6  %) and more @entity283 perceived themselves to be working largely or completely in accordance with the CS (89.2 versus 79.0  %) than in 2010. A comparison of the results in specific pilot regions with the rest of the country revealed that @entity283 in these regions scored significantly more positively on implementation and appreciation of the CS. This positive trend was reflected by the high levels of reported @entity1 satisfaction and involvement in treatment. @entity283 who were in possession of the CS had significantly better scores on the implementation of several elements of the CS than @entity283 who were not in possession of the CS. CONCLUSION: The CS has become more prominent and embedded in daily health care practice. In retrospect the CS has provided momentum for the realization of various processes relating to the wider implementation of standards to improve the care for @entity1 with other @entity102 in the Netherlands. Experiences with the NAD and CS underline the need to move towards an integrated multidisciplinary approach of @entity6 care worldwide.

title: The implementation of national action program XXXX in the Netherlands: lessons learned.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient', 'people']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic diseases']

entities_list: @entity283 :: ('OMIM:603663', 'Disease') :: ['health care professionals', 'HCPs']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: UNASSIGNED: Identification of @entity1 with @entity6950 -induced @entity882 is encumbered by false positive enzyme-linked immuno assay (ELISA) antibody results, therefore a @entity750 release assay (SRA) is used for confirmation. Recently, several studies have demonstrated that increasing the optical density (OD) threshold (currently at 0.4) of the antibody test enhances the positive predictive value. The purpose of this study was to determine the frequency of @entity1 who were ELISA antibody positive but SRA negative, and the costs and @entity548 events associated with alternative anticoagulant treatment. We hypothesized that treating @entity1 with a positive ELISA antibody OD value of <1.0 would result in increased cost and @entity548 risk. This retrospective chart review was conducted on adult hospitalized @entity1 from 2011 to 2013. @entity1 with positive ELISA antibodies (OD of 0.4-1.0) and an SRA result were included. Eighty-five @entity1 were identified with positive antibodies (average OD of 0.66), 100  % of which were found to be SRA negative. A total of 59 @entity1 (69  %) received alternative anticoagulants. The average duration of treatment was 3.1  days, and 4 @entity1 (4.7  %) experienced a @entity548 event. The cost of testing and laboratory monitoring was  36,346 and the cost of the alternative anticoagulants totaled  47,179. The total cost was  83,525, with an average total cost per @entity1 of  982. This study adds to the body of literature suggesting treatment should only be initiated if the OD is one or greater. The high false positive rate caused increased cost and some @entity548 events.

title: Consequences of treating false positive XXXX -induced @entity882 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']

answer: @entity6950 :: (MESH:D006493,Chemical) :: ['heparin']


abstract: UNASSIGNED: Identification of @entity1 with @entity6950 -induced @entity882 is encumbered by false positive enzyme-linked immuno assay (ELISA) antibody results, therefore a @entity750 release assay (SRA) is used for confirmation. Recently, several studies have demonstrated that increasing the optical density (OD) threshold (currently at 0.4) of the antibody test enhances the positive predictive value. The purpose of this study was to determine the frequency of @entity1 who were ELISA antibody positive but SRA negative, and the costs and @entity548 events associated with alternative anticoagulant treatment. We hypothesized that treating @entity1 with a positive ELISA antibody OD value of <1.0 would result in increased cost and @entity548 risk. This retrospective chart review was conducted on adult hospitalized @entity1 from 2011 to 2013. @entity1 with positive ELISA antibodies (OD of 0.4-1.0) and an SRA result were included. Eighty-five @entity1 were identified with positive antibodies (average OD of 0.66), 100  % of which were found to be SRA negative. A total of 59 @entity1 (69  %) received alternative anticoagulants. The average duration of treatment was 3.1  days, and 4 @entity1 (4.7  %) experienced a @entity548 event. The cost of testing and laboratory monitoring was  36,346 and the cost of the alternative anticoagulants totaled  47,179. The total cost was  83,525, with an average total cost per @entity1 of  982. This study adds to the body of literature suggesting treatment should only be initiated if the OD is one or greater. The high false positive rate caused increased cost and some @entity548 events.

title: Consequences of treating false positive @entity6950 -induced XXXX .

answer: @entity882 :: (MESH:D013921,Disease) :: ['thrombocytopenia']


abstract: @entity158 has been reported in association with a variety of antidepressants such as the tricyclic antidepressants (TCAs, e.g. @entity8991 , @entity2645 , @entity5829 , @entity6700 , @entity19584 ), the selective @entity750 reuptake inhibitors (SSRIs, e.g. @entity905 ), @entity906 and the MAOIs. Apart from lowering the dose and changing the antidepressant, no strategies are available to treat this side effect. In this paper, @entity158 following the administration of @entity18891 is described in two @entity1 . Both @entity1 were treated concomitantly with the selective alpha(1A)-adrenoceptor antagonist, @entity9940 . A re-challenge was performed in one @entity1 . The Hamilton Depression Rating Scale (HAM-D), the American Urological Association symptom index, a (dis)satisfaction item score and the Udvalg for Kliniske Undersoegelser (UKU-side effect rating scale) were used to assess the treatment. @entity9940 rapidly and completely resolved the @entity158 and urinary hesitancy in both @entity1 . A re-challenge in one @entity1 resulted in a prompt reappearance of both side effects. @entity9940 resolved the problem of @entity158 in these @entity1 ; however, larger studies are needed to confirm these results.

title: XXXX and urinary hesitancy in association with antidepressant therapy: relief with @entity9940 .

entities_list: @entity6700 :: ('MESH:D011530', 'Chemical') :: ['protriptyline']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity19584 :: ('MESH:D000657', 'Chemical') :: ['amoxapine']

entities_list: @entity8991 :: ('MESH:D002997', 'Chemical') :: ['clomipramine']

entities_list: @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine']

entities_list: @entity5829 :: ('MESH:D003891', 'Chemical') :: ['desipramine']

entities_list: @entity18891 :: ('MESH:C074679', 'Chemical') :: ['reboxetine']

entities_list: @entity2645 :: ('MESH:D007099', 'Chemical') :: ['imipramine']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['painful ejaculation', 'Painful ejaculation']

entities_list: @entity906 :: ('MESH:C047426', 'Chemical') :: ['venlafaxine']

entities_list: @entity9940 :: ('MESH:C088482', 'Chemical') :: ['Tamsulosin', 'tamsulosin']

answer: @entity158 :: (MESH:D010146,Disease) :: ['Painful ejaculation']


abstract: @entity158 has been reported in association with a variety of antidepressants such as the tricyclic antidepressants (TCAs, e.g. @entity8991 , @entity2645 , @entity5829 , @entity6700 , @entity19584 ), the selective @entity750 reuptake inhibitors (SSRIs, e.g. @entity905 ), @entity906 and the MAOIs. Apart from lowering the dose and changing the antidepressant, no strategies are available to treat this side effect. In this paper, @entity158 following the administration of @entity18891 is described in two @entity1 . Both @entity1 were treated concomitantly with the selective alpha(1A)-adrenoceptor antagonist, @entity9940 . A re-challenge was performed in one @entity1 . The Hamilton Depression Rating Scale (HAM-D), the American Urological Association symptom index, a (dis)satisfaction item score and the Udvalg for Kliniske Undersoegelser (UKU-side effect rating scale) were used to assess the treatment. @entity9940 rapidly and completely resolved the @entity158 and urinary hesitancy in both @entity1 . A re-challenge in one @entity1 resulted in a prompt reappearance of both side effects. @entity9940 resolved the problem of @entity158 in these @entity1 ; however, larger studies are needed to confirm these results.

title: @entity158 and urinary hesitancy in association with antidepressant therapy: relief with XXXX .

answer: @entity9940 :: (MESH:C088482,Chemical) :: ['tamsulosin']


abstract: INTRODUCTION: @entity1084 is characterized by the retention of gastric contents. Removal of gastric contents is an important part of the treatment strategy. The use of a nasogastric tube alone can result in inadequate removal of gastric contents. We treated a @entity1 with advanced @entity356 and @entity1084 with pancrelipase to aid in the removal of gastric contents. PRESENTATION OF CASE: The @entity1 is an 81-year-old @entity1 with a Type 3 @entity356 nearly circumferentially involving the antrum, resulting in @entity1084 . A nasogastric tube was placed for four days, but drainage of gastric contents was inadequate. Pancrelipase was then given orally for four days, and gastric contents were evacuated. The @entity1 underwent distal gastrectomy with Roux-en-Y reconstruction and was discharged from the hospital on postoperative day 14. DISCUSSION: This report suggests that pancrelipase may be beneficial in the treatment of @entity1 with @entity1084 . CONCLUSION: Pancrelipase allowed gastric contents to be evacuated in a short period of time in a @entity1 with @entity1084 .

title: Pretreatment of XXXX with pancrelipase: Report of a case.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man']

entities_list: @entity1084 :: ('MESH:D017219', 'Disease') :: ['gastric outlet obstruction', 'Gastric outlet obstruction']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

answer: @entity1084 :: (MESH:D017219,Disease) :: ['gastric outlet obstruction']


abstract: INTRODUCTION: @entity521 is the most common extracranial solid pediatric malignancy. The most common site is abdomen with predominance of suprarenal medulla. Infiltration of the @entity5 to the liver is rare. No cases were reported in the literature about the misdiagnosis of @entity521 as @entity4607 in the liver. PRESENTATION OF CASE: We represent a rare case of @entity521 misdiagnosed as @entity4607 in liver in a six-month-old female @entity1 presented with @entity221 and abdominal mass. Abdominal computed tomography (CT) revealed @entity5409 occupying most of the right liver enchroaching upon right suprarenal region and displacing the right kidney inferior suggestive for @entity4607 . Right adrenalectomy with en-bloc resection of the adjacent liver segments was done. Postoperative pathology revealed @entity521 with positive specific immunohistochemistry (IHC). DISCUSSION: Although @entity521 is the second most common pediatric abdominal malignancy with specific diagnostic modalities, a misdiagnosis of a case with @entity521 as @entity4607 is rare. Histopathological diagnosis of @entity521 with positive IHC is essential as shown in our case. CONCLUSION: We represent a rare case of @entity521 which arose from the right adrenal gland and infiltrated the adjacent liver substance mimicking @entity409 . @entity521 is rarely presented with pyrexia of unknown origin. @entity521 should be considered in differential diagnosis of abdominal mass in all @entity1 and @entity1 .

title: Right adrenal gland neuroblastoma infiltrating the liver and mimicking XXXX : A case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'infants', 'infant']

entities_list: @entity5409 :: ('MESH:D052177', 'Disease') :: ['large cystic lesion']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['mesenchymal hamartoma of the liver']

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma', 'Neuroblastoma']

entities_list: @entity4607 :: ('MESH:D006222', 'Disease') :: ['mesenchymal hamartoma']

answer: @entity4607 :: (MESH:D006222,Disease) :: ['mesenchymal hamartoma']


abstract: Expression of @entity13770 protein in 50 @entity5 , @entity3 and recurrent @entity5 of @entity14 has been analyzed by immunohistochemistry. Sixty percent of the @entity5 were at least focally positive for the antigen. There was no correlation between @entity13770 expression and histologic grade of the lesions. In contrast, @entity13770 expression in T4 and T3 @entity5 was significantly higher than in T2 @entity189 . Immunoreactions in @entity189 with distant @entity3 (MI) were stronger than in M0 cases. However, this difference did not reach statistical significance. The presence of lymph node @entity3 did not correlate with @entity13770 expression. High expression of @entity13770 in T4 and T3 @entity189 together with the finding of pronounced expression of the antigen at invasion fronts in single cases could be interpreted as a function in @entity5 cell invasion and motility. However, in @entity3 and recurrent @entity5 , @entity13770 expression did not differ from primary lesions (53% positive lesions). All in all, under consideration of the latter finding in particular and together with the randomly distributed immunopositive @entity5 cells and cell clusters in the majority of cases, it is more likely that the expression pattern of @entity13770 in @entity14 is a result of overall @entity5 cell heterogeneity.

title: The @entity13770 protein in XXXX and @entity3 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'primary tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal carcinomas']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal carcinomas']


abstract: Expression of @entity13770 protein in 50 @entity5 , @entity3 and recurrent @entity5 of @entity14 has been analyzed by immunohistochemistry. Sixty percent of the @entity5 were at least focally positive for the antigen. There was no correlation between @entity13770 expression and histologic grade of the lesions. In contrast, @entity13770 expression in T4 and T3 @entity5 was significantly higher than in T2 @entity189 . Immunoreactions in @entity189 with distant @entity3 (MI) were stronger than in M0 cases. However, this difference did not reach statistical significance. The presence of lymph node @entity3 did not correlate with @entity13770 expression. High expression of @entity13770 in T4 and T3 @entity189 together with the finding of pronounced expression of the antigen at invasion fronts in single cases could be interpreted as a function in @entity5 cell invasion and motility. However, in @entity3 and recurrent @entity5 , @entity13770 expression did not differ from primary lesions (53% positive lesions). All in all, under consideration of the latter finding in particular and together with the randomly distributed immunopositive @entity5 cells and cell clusters in the majority of cases, it is more likely that the expression pattern of @entity13770 in @entity14 is a result of overall @entity5 cell heterogeneity.

title: The @entity13770 protein in @entity14 and XXXX .

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: Expression of @entity13770 protein in 50 @entity5 , @entity3 and recurrent @entity5 of @entity14 has been analyzed by immunohistochemistry. Sixty percent of the @entity5 were at least focally positive for the antigen. There was no correlation between @entity13770 expression and histologic grade of the lesions. In contrast, @entity13770 expression in T4 and T3 @entity5 was significantly higher than in T2 @entity189 . Immunoreactions in @entity189 with distant @entity3 (MI) were stronger than in M0 cases. However, this difference did not reach statistical significance. The presence of lymph node @entity3 did not correlate with @entity13770 expression. High expression of @entity13770 in T4 and T3 @entity189 together with the finding of pronounced expression of the antigen at invasion fronts in single cases could be interpreted as a function in @entity5 cell invasion and motility. However, in @entity3 and recurrent @entity5 , @entity13770 expression did not differ from primary lesions (53% positive lesions). All in all, under consideration of the latter finding in particular and together with the randomly distributed immunopositive @entity5 cells and cell clusters in the majority of cases, it is more likely that the expression pattern of @entity13770 in @entity14 is a result of overall @entity5 cell heterogeneity.

title: The XXXX protein in @entity14 and @entity3 .

answer: @entity13770 :: (338412,Gene) :: ['pS2']


abstract: BACKGROUND: New-onset @entity6 after transplant (NODAT) is associated with serious morbidity and mortality. The incidence of NODAT is higher with @entity1140 ( @entity5467 ) compared with @entity205 ( @entity9472 ); however, the effects of switching from @entity5467 to @entity9472 in NODAT have not been studied well. MATERIALS AND METHODS: This was a single-center, open-label, prospective, randomized study, including renal transplant recipients who were on @entity5467 -based immunosuppression and developed NODAT. Those with pretransplant @entity6 , @entity56 to @entity9472 or @entity5467 , severe @entity281 , and denying consent were excluded. Subjects were randomized to either switch to @entity9472 or to continue on @entity5467 . Fasting and postprandial plasma @entity413 , fasting insulin and C-peptide levels, insulin and oral hypoglycaemic agents (OHA) use were monitored monthly for 3 months, whereas glycosylated haemoglobin (HbA1c) was checked at baseline and 3 months. RESULTS: Sixty-seven subjects were randomized to switch to @entity9472 (n  = 32) or continuation of @entity5467 (n  = 35). Both groups had similar baseline characteristics. After randomization, there was significant improvement in fasting plasma @entity413 , fasting insulin levels, C-peptide levels, and insulin requirement in both groups, whereas @entity4051 c improved significantly only in the @entity9472 group. The decline in fasting plasma @entity413 and insulin requirement was more significant in subjects on @entity9472 . An equal number of subjects in each group (59.4% in @entity9472 group and 40% in @entity5467 group, P  = ns) had resolution of NODAT. @entity1017 was more significant in the @entity9472 group; however, there was no difference in other side effects or rejection episodes. CONCLUSIONS: A switch from @entity1140 to @entity205 is a safe and effective strategy in @entity1 with NODAT.

title: Conversion from @entity1140 to XXXX in @entity1 with new-onset @entity6 after renal transplant: an open-label randomized prospective pilot study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['Weight gain']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity205 :: (MESH:D016572,Chemical) :: ['cyclosporine']


abstract: BACKGROUND: New-onset @entity6 after transplant (NODAT) is associated with serious morbidity and mortality. The incidence of NODAT is higher with @entity1140 ( @entity5467 ) compared with @entity205 ( @entity9472 ); however, the effects of switching from @entity5467 to @entity9472 in NODAT have not been studied well. MATERIALS AND METHODS: This was a single-center, open-label, prospective, randomized study, including renal transplant recipients who were on @entity5467 -based immunosuppression and developed NODAT. Those with pretransplant @entity6 , @entity56 to @entity9472 or @entity5467 , severe @entity281 , and denying consent were excluded. Subjects were randomized to either switch to @entity9472 or to continue on @entity5467 . Fasting and postprandial plasma @entity413 , fasting insulin and C-peptide levels, insulin and oral hypoglycaemic agents (OHA) use were monitored monthly for 3 months, whereas glycosylated haemoglobin (HbA1c) was checked at baseline and 3 months. RESULTS: Sixty-seven subjects were randomized to switch to @entity9472 (n  = 32) or continuation of @entity5467 (n  = 35). Both groups had similar baseline characteristics. After randomization, there was significant improvement in fasting plasma @entity413 , fasting insulin levels, C-peptide levels, and insulin requirement in both groups, whereas @entity4051 c improved significantly only in the @entity9472 group. The decline in fasting plasma @entity413 and insulin requirement was more significant in subjects on @entity9472 . An equal number of subjects in each group (59.4% in @entity9472 group and 40% in @entity5467 group, P  = ns) had resolution of NODAT. @entity1017 was more significant in the @entity9472 group; however, there was no difference in other side effects or rejection episodes. CONCLUSIONS: A switch from @entity1140 to @entity205 is a safe and effective strategy in @entity1 with NODAT.

title: Conversion from XXXX to @entity205 in @entity1 with new-onset @entity6 after renal transplant: an open-label randomized prospective pilot study.

answer: @entity1140 :: (MESH:D016559,Chemical) :: ['tacrolimus']


abstract: BACKGROUND: New-onset @entity6 after transplant (NODAT) is associated with serious morbidity and mortality. The incidence of NODAT is higher with @entity1140 ( @entity5467 ) compared with @entity205 ( @entity9472 ); however, the effects of switching from @entity5467 to @entity9472 in NODAT have not been studied well. MATERIALS AND METHODS: This was a single-center, open-label, prospective, randomized study, including renal transplant recipients who were on @entity5467 -based immunosuppression and developed NODAT. Those with pretransplant @entity6 , @entity56 to @entity9472 or @entity5467 , severe @entity281 , and denying consent were excluded. Subjects were randomized to either switch to @entity9472 or to continue on @entity5467 . Fasting and postprandial plasma @entity413 , fasting insulin and C-peptide levels, insulin and oral hypoglycaemic agents (OHA) use were monitored monthly for 3 months, whereas glycosylated haemoglobin (HbA1c) was checked at baseline and 3 months. RESULTS: Sixty-seven subjects were randomized to switch to @entity9472 (n  = 32) or continuation of @entity5467 (n  = 35). Both groups had similar baseline characteristics. After randomization, there was significant improvement in fasting plasma @entity413 , fasting insulin levels, C-peptide levels, and insulin requirement in both groups, whereas @entity4051 c improved significantly only in the @entity9472 group. The decline in fasting plasma @entity413 and insulin requirement was more significant in subjects on @entity9472 . An equal number of subjects in each group (59.4% in @entity9472 group and 40% in @entity5467 group, P  = ns) had resolution of NODAT. @entity1017 was more significant in the @entity9472 group; however, there was no difference in other side effects or rejection episodes. CONCLUSIONS: A switch from @entity1140 to @entity205 is a safe and effective strategy in @entity1 with NODAT.

title: Conversion from @entity1140 to @entity205 in @entity1 with new-onset XXXX after renal transplant: an open-label randomized prospective pilot study.

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: BACKGROUND: New-onset @entity6 after transplant (NODAT) is associated with serious morbidity and mortality. The incidence of NODAT is higher with @entity1140 ( @entity5467 ) compared with @entity205 ( @entity9472 ); however, the effects of switching from @entity5467 to @entity9472 in NODAT have not been studied well. MATERIALS AND METHODS: This was a single-center, open-label, prospective, randomized study, including renal transplant recipients who were on @entity5467 -based immunosuppression and developed NODAT. Those with pretransplant @entity6 , @entity56 to @entity9472 or @entity5467 , severe @entity281 , and denying consent were excluded. Subjects were randomized to either switch to @entity9472 or to continue on @entity5467 . Fasting and postprandial plasma @entity413 , fasting insulin and C-peptide levels, insulin and oral hypoglycaemic agents (OHA) use were monitored monthly for 3 months, whereas glycosylated haemoglobin (HbA1c) was checked at baseline and 3 months. RESULTS: Sixty-seven subjects were randomized to switch to @entity9472 (n  = 32) or continuation of @entity5467 (n  = 35). Both groups had similar baseline characteristics. After randomization, there was significant improvement in fasting plasma @entity413 , fasting insulin levels, C-peptide levels, and insulin requirement in both groups, whereas @entity4051 c improved significantly only in the @entity9472 group. The decline in fasting plasma @entity413 and insulin requirement was more significant in subjects on @entity9472 . An equal number of subjects in each group (59.4% in @entity9472 group and 40% in @entity5467 group, P  = ns) had resolution of NODAT. @entity1017 was more significant in the @entity9472 group; however, there was no difference in other side effects or rejection episodes. CONCLUSIONS: A switch from @entity1140 to @entity205 is a safe and effective strategy in @entity1 with NODAT.

title: Conversion from @entity1140 to @entity205 in XXXX with new-onset @entity6 after renal transplant: an open-label randomized prospective pilot study.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: We aimed to investigate whether low post-transplantation-period hemoglobin levels are predictive of @entity65 in terms of left ventricular (LV) @entity1184 and @entity455 and to determine the contributing factors of post-transplantation @entity417 in kidney transplant (KT) recipients. METHODS: One hundred fifty (mean age, 38.9    10.8  y; 113 male) KT recipients with functioning grafts were enrolled in the study. All subjects underwent clinical and laboratory evaluations (24-hour urinary protein loss, complete blood count) and transthoracic echocardiography to assess LV systolic function. Arterial stiffness was measured by means of carotid-femoral pulse-wave velocity ( @entity122 ). Mean hemoglobin levels were analyzed at the 1st, 6th, 12th, and 24th months after transplantation. @entity1 were divided into 2 groups according to presence of @entity417 : @entity1 with @entity417 (group 1; n  = 120) and normal (group 2; n  = 30). RESULTS: @entity122 values (6.8    1.9  m/s vs 6.4    1.1  m/s in groups 1 and 2, respectively; P  = .002) and LV mass index (LVMI; 252.1    93.7  g/m(2) vs 161.2    38.5  g/m(2) groups 1 and 2, respectively; P  = .001) were significantly higher in group 1. Estimated glomerular filtration rate and (64    28.5  m/min vs 77.8    30  m/min in groups 1 and 2, respectively; P  = .001) LV systolic function (57.2    5.8% vs 77.8    30% in groups 1 and 2, respectively; P  < .005) were significantly lower in group 1. In regression analysis, LV systolic function and LVMI were predictors of post-transplantation hemoglobin levels. CONCLUSIONS: Post-transplantation @entity417 contributes to @entity65 by deteriorating LV function and increasing @entity122 and is therefore associated with poor prognosis for graft survival. Early correction of post-transplantation @entity417 , especially with the use of @entity1307 , may be beneficial for both graft and recipient survivals.

title: Post-transplantation Anemia Predicts XXXX and Poor Graft Function in Kidney Transplant Recipients.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular stiffness']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity1307 :: ('2056', 'Gene') :: ['erythropoietin']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular morbidity']

answer: @entity65 :: (MESH:D002318,Disease) :: ['Cardiovascular Morbidity']


abstract: Activation of cardiac sympathetic afferents elicits @entity158 and excitatory cardiovascular reflexes including acute @entity101 and @entity591 . Our previous studies have shown that specific regions in the medulla, such as the nucleus of solitary tract and ventrolateral medulla, are involved in central regulation of cardiac sympathoexcitatory reflexes. However, the contributions of supramedullary nuclei to these reflexes have not been characterized. In the present study, we located activated neurons in the pons and midbrain induced by inputs from cardiac sympathetic afferents by detecting their @entity19222 immunoreactivity. In anesthetized @entity468 with bilateral carotid denervation and cervical vagotomy, epicardial application of @entity1812 (1-10 microg, in 0.1 ml; n=7) was performed on the anterior surface of the left ventricle six times, every 20 min. Repetitive application of @entity1812 caused consistent excitatory cardiovascular reflexes characterized by increases in blood pressure and heart rate. No responses were evoked by the vehicle for @entity1812 (0.9% saline, n=7). Compared to control @entity468 , @entity19222 immunoreactive cells were significantly increased (P<0.05) in the rostral pons, caudal and intermediate midbrain in the @entity1812 -treated @entity468 . The specific areas activated include the parabrachial nucleus, K  lliker-Fuse nucleus, locus coeruleus, dorsal nucleus of raphe, and dorsal, lateral and ventrolateral periaqueductal gray. From these results we suggest that cardiovascular-related regions in the pons and midbrain form part of a long loop in central integration of cardiac sympathoexcitatory reflexes.

title: Central pathways in the pons and midbrain involved in cardiac sympathoexcitatory reflexes in XXXX .

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachyarrhythmias']

entities_list: @entity1812 :: ('MESH:D001920', 'Chemical') :: ['bradykinin']

answer: @entity468 :: (9685,Species) :: ['cats']


abstract: OBJECTIVE: The aim of this study was to determine the types, incidence, and risk factors for early postoperative @entity358 in heart transplant recipients. METHODS: We retrospectively collected data from the records of consecutive heart transplantations from January 2003 to December 2013. A total of 83 @entity1 underwent heart transplantation. The data collected for each case were demographic features, duration of mechanical ventilation, respiratory problems that developed during the intensive care unit (ICU) stay, and early postoperative mortality (<30  d). RESULTS: Of the 72 @entity1 considered, 52 (72.2%) were male. The overall mean age at the time of transplantation was 32.1    16.6 years. Twenty-five @entity1 (34.7%) developed @entity260 . The most frequent problem was @entity1143 (n  = 19; 26.4%), followed by @entity891 (n  = 6; 8.3%), acute @entity649 (n  = 5; 6.9%), @entity3126 (n  = 4; 5.6%), and @entity55 (n  = 3; 4.2%). Postoperative duration of mechanical ventilation (44.2    59.2  h vs 123.8    190.8 h; P  = .005) and the length of postoperative ICU stay (10.1    5.8  h vs 19.8    28.9 h; P  = .03) were longer among @entity1 who had respiratory problems. Postoperative length of stay in the hospital (22.3    12.5  d vs 30.3    38.3 d; P  = .75) was similar in the 2 groups. The overall mortality rate was 12.5% (n  = 9). The @entity1 who had respiratory problems did not show higher mortality than those who did not have respiratory problems (16.0% vs 10.6%; P  = .71). CONCLUSIONS: Respiratory complications were relatively common in our cohort of heart transplant recipients. However, these complications were mostly self-limiting and did not result in worse mortality.

title: Early postoperative XXXX after heart transplantation.

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion']

entities_list: @entity3126 :: ('MESH:D011654', 'Disease') :: ['pulmonary edema']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['respiratory distress syndrome']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['early postoperative respiratory complications']

entities_list: @entity891 :: ('MESH:D001261', 'Disease') :: ['atelectasis']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary complications']

answer: @entity358 :: (MESH:D008171,Disease) :: ['pulmonary complications']


abstract: BACKGROUND: Population-based figures on @entity1489 are essential for a realistic assessment of the personal disease burden, prevention modes and the need for caring. The Robert Koch Institute in Germany estimates the incidence of @entity1489 as seven cases in 100 000 @entity1 (age-standardized by the European standard rate). Population-based studies presumably show higher incidence rates of 10-16 cases in 100 000 @entity1 . Few data exist for @entity1489 ( @entity1489 ) as this is not systematically registered in Germany. OBJECTIVES: To present the first population-based results from the Schleswig-Holstein (Germany) Cancer Registry on incidence, stage distribution, clinical types and localization of @entity1489 and to compare the results with other studies. METHODS: The Cancer Registry of the Bundesland Schleswig-Holstein with 3500 registering institutions, 100 of which are dermatological institutions, investigates all notifiable incident @entity5 cases according to international standards. From the recorded data all @entity320 and @entity1489 cases were identified and evaluated. RESULTS: Between 1998 and 2001, 1784 @entity320 ( @entity320 ) and 12 956 @entity1489 cases underwent diagnostic and analytical evaluation. For @entity320 , age-standardized incidence rates were 12.3 and 14.8 in 100 000 @entity1 and @entity1 , respectively, and the mean age of @entity1 was greater than that of @entity1 (56.6 vs. 54.9 years, P < 0.05). @entity320 was the most frequent clinical type (39.1%). The @entity5 were predominantly located on the trunk in @entity1 (46.8%) in contrast to leg and hip in @entity1 (39.5%). For @entity1489 , the age-standardized incidence rates were 100.2 and 72.6 in 100 000 @entity1 and @entity1 , respectively. More than 80% of all @entity5 were @entity1491 . CONCLUSIONS: The first population-based data from Schleswig-Holstein on the characteristics (age, sex, histological subtypes, localization and stage) of @entity1489 agree well with the existing literature and may thus be regarded as representative. However, markedly higher incidences for @entity320 and @entity1489 in the north of Germany compared with other parts of the country were observed. As the incidence rates from the north of Germany fit well into the European geographical pattern, we assume no regional increase. Therefore, the official German estimates on cutaneous @entity5 may largely depend on regional factors and may not be regarded as representative for all regions in Germany.

title: Epidemiology of XXXX and @entity1489 in Schleswig-Holstein, Germany: incidence, clinical subtypes, @entity5 stages and localization (epidemiology of @entity1489 ).

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'persons', 'men']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumours']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['non-melanoma skin cancer', 'melanoma skin cancer', 'NMSC', 'skin tumours', 'skin cancer']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'MM', 'malignant melanoma', 'Superficial spreading melanoma']

entities_list: @entity1491 :: ('MESH:D002280', 'Disease') :: ['basal cell carcinoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['cutaneous melanoma']


abstract: BACKGROUND: Population-based figures on @entity1489 are essential for a realistic assessment of the personal disease burden, prevention modes and the need for caring. The Robert Koch Institute in Germany estimates the incidence of @entity1489 as seven cases in 100 000 @entity1 (age-standardized by the European standard rate). Population-based studies presumably show higher incidence rates of 10-16 cases in 100 000 @entity1 . Few data exist for @entity1489 ( @entity1489 ) as this is not systematically registered in Germany. OBJECTIVES: To present the first population-based results from the Schleswig-Holstein (Germany) Cancer Registry on incidence, stage distribution, clinical types and localization of @entity1489 and to compare the results with other studies. METHODS: The Cancer Registry of the Bundesland Schleswig-Holstein with 3500 registering institutions, 100 of which are dermatological institutions, investigates all notifiable incident @entity5 cases according to international standards. From the recorded data all @entity320 and @entity1489 cases were identified and evaluated. RESULTS: Between 1998 and 2001, 1784 @entity320 ( @entity320 ) and 12 956 @entity1489 cases underwent diagnostic and analytical evaluation. For @entity320 , age-standardized incidence rates were 12.3 and 14.8 in 100 000 @entity1 and @entity1 , respectively, and the mean age of @entity1 was greater than that of @entity1 (56.6 vs. 54.9 years, P < 0.05). @entity320 was the most frequent clinical type (39.1%). The @entity5 were predominantly located on the trunk in @entity1 (46.8%) in contrast to leg and hip in @entity1 (39.5%). For @entity1489 , the age-standardized incidence rates were 100.2 and 72.6 in 100 000 @entity1 and @entity1 , respectively. More than 80% of all @entity5 were @entity1491 . CONCLUSIONS: The first population-based data from Schleswig-Holstein on the characteristics (age, sex, histological subtypes, localization and stage) of @entity1489 agree well with the existing literature and may thus be regarded as representative. However, markedly higher incidences for @entity320 and @entity1489 in the north of Germany compared with other parts of the country were observed. As the incidence rates from the north of Germany fit well into the European geographical pattern, we assume no regional increase. Therefore, the official German estimates on cutaneous @entity5 may largely depend on regional factors and may not be regarded as representative for all regions in Germany.

title: Epidemiology of @entity320 and @entity1489 in Schleswig-Holstein, Germany: incidence, clinical subtypes, XXXX stages and localization (epidemiology of @entity1489 ).

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumour']


abstract: BACKGROUND: Population-based figures on @entity1489 are essential for a realistic assessment of the personal disease burden, prevention modes and the need for caring. The Robert Koch Institute in Germany estimates the incidence of @entity1489 as seven cases in 100 000 @entity1 (age-standardized by the European standard rate). Population-based studies presumably show higher incidence rates of 10-16 cases in 100 000 @entity1 . Few data exist for @entity1489 ( @entity1489 ) as this is not systematically registered in Germany. OBJECTIVES: To present the first population-based results from the Schleswig-Holstein (Germany) Cancer Registry on incidence, stage distribution, clinical types and localization of @entity1489 and to compare the results with other studies. METHODS: The Cancer Registry of the Bundesland Schleswig-Holstein with 3500 registering institutions, 100 of which are dermatological institutions, investigates all notifiable incident @entity5 cases according to international standards. From the recorded data all @entity320 and @entity1489 cases were identified and evaluated. RESULTS: Between 1998 and 2001, 1784 @entity320 ( @entity320 ) and 12 956 @entity1489 cases underwent diagnostic and analytical evaluation. For @entity320 , age-standardized incidence rates were 12.3 and 14.8 in 100 000 @entity1 and @entity1 , respectively, and the mean age of @entity1 was greater than that of @entity1 (56.6 vs. 54.9 years, P < 0.05). @entity320 was the most frequent clinical type (39.1%). The @entity5 were predominantly located on the trunk in @entity1 (46.8%) in contrast to leg and hip in @entity1 (39.5%). For @entity1489 , the age-standardized incidence rates were 100.2 and 72.6 in 100 000 @entity1 and @entity1 , respectively. More than 80% of all @entity5 were @entity1491 . CONCLUSIONS: The first population-based data from Schleswig-Holstein on the characteristics (age, sex, histological subtypes, localization and stage) of @entity1489 agree well with the existing literature and may thus be regarded as representative. However, markedly higher incidences for @entity320 and @entity1489 in the north of Germany compared with other parts of the country were observed. As the incidence rates from the north of Germany fit well into the European geographical pattern, we assume no regional increase. Therefore, the official German estimates on cutaneous @entity5 may largely depend on regional factors and may not be regarded as representative for all regions in Germany.

title: Epidemiology of @entity320 and XXXX in Schleswig-Holstein, Germany: incidence, clinical subtypes, @entity5 stages and localization (epidemiology of @entity1489 ).

answer: @entity1489 :: (MESH:D012878,Disease) :: ['non-melanoma skin cancer']


abstract: BACKGROUND: Population-based figures on @entity1489 are essential for a realistic assessment of the personal disease burden, prevention modes and the need for caring. The Robert Koch Institute in Germany estimates the incidence of @entity1489 as seven cases in 100 000 @entity1 (age-standardized by the European standard rate). Population-based studies presumably show higher incidence rates of 10-16 cases in 100 000 @entity1 . Few data exist for @entity1489 ( @entity1489 ) as this is not systematically registered in Germany. OBJECTIVES: To present the first population-based results from the Schleswig-Holstein (Germany) Cancer Registry on incidence, stage distribution, clinical types and localization of @entity1489 and to compare the results with other studies. METHODS: The Cancer Registry of the Bundesland Schleswig-Holstein with 3500 registering institutions, 100 of which are dermatological institutions, investigates all notifiable incident @entity5 cases according to international standards. From the recorded data all @entity320 and @entity1489 cases were identified and evaluated. RESULTS: Between 1998 and 2001, 1784 @entity320 ( @entity320 ) and 12 956 @entity1489 cases underwent diagnostic and analytical evaluation. For @entity320 , age-standardized incidence rates were 12.3 and 14.8 in 100 000 @entity1 and @entity1 , respectively, and the mean age of @entity1 was greater than that of @entity1 (56.6 vs. 54.9 years, P < 0.05). @entity320 was the most frequent clinical type (39.1%). The @entity5 were predominantly located on the trunk in @entity1 (46.8%) in contrast to leg and hip in @entity1 (39.5%). For @entity1489 , the age-standardized incidence rates were 100.2 and 72.6 in 100 000 @entity1 and @entity1 , respectively. More than 80% of all @entity5 were @entity1491 . CONCLUSIONS: The first population-based data from Schleswig-Holstein on the characteristics (age, sex, histological subtypes, localization and stage) of @entity1489 agree well with the existing literature and may thus be regarded as representative. However, markedly higher incidences for @entity320 and @entity1489 in the north of Germany compared with other parts of the country were observed. As the incidence rates from the north of Germany fit well into the European geographical pattern, we assume no regional increase. Therefore, the official German estimates on cutaneous @entity5 may largely depend on regional factors and may not be regarded as representative for all regions in Germany.

title: Epidemiology of @entity320 and @entity1489 in Schleswig-Holstein, Germany: incidence, clinical subtypes, @entity5 stages and localization (epidemiology of XXXX ).

answer: @entity1489 :: (MESH:D012878,Disease) :: ['skin cancer']


abstract: BACKGROUND AND PURPOSE: Surgery is the standard of care in stage I @entity1149 ( @entity1149 ), but stereotactic ablative radiotherapy (SABR) is increasingly used to treat @entity1 at high-risk for surgical complications. We studied which @entity1 - and clinician-related characteristics influenced treatment recommendations. MATERIAL AND METHODS: A binary choice experiment with hypothetical cases was conducted. Cases varied on five @entity1 -related characteristics: @entity1 age, @entity1030 Global Initiative for @entity1030 ( @entity1030 ) score, Charlson co-morbidity index, World Health Organization performance status (WHO-PS) and @entity1 treatment preference (surgery/SABR). Clinician characteristics were recorded. Responses were analyzed using generalized linear mixed models. RESULTS: 126 clinicians completed the survey. All @entity1 -related characteristics, the clinician speciality, and whether clinicians considered outcomes of surgery comparable to SABR, significantly influenced treatment recommendations. Pulmonologists were most influenced by WHO-PS and comorbidity, whereas comorbidity and age had greatest influence on radiation oncologists and surgeons. Clinicians were less influenced by stated @entity1 preference and @entity1030 score. Limited consistency was observed in treatment recommendations. CONCLUSIONS: This study suggests that more efforts are needed to develop uniform approaches for making treatment recommendations, and also to incorporate @entity1 preferences when making treatment decisions for stage I @entity1149 .

title: Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I XXXX : A binary choice experiment.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['Chronic Obstructive Lung Disease', 'Chronic Obstructive Pulmonary Disease', 'COPD GOLD']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: BACKGROUND: @entity282 is a well-recognized problem after various types of surgery such as amputation, thoracotomy, mastectomy, gallbladder surgery and @entity169 . However, little is known about @entity1118 after gynaecologic surgery. Therefore, the aim was to study the incidence of @entity1118 after Caesarean section. METHODS: A questionnaire was sent in February/March 2003 to 244 consecutive @entity1 who underwent Caesarean section in a one-year period from 1 October 2001 to 30 September 2002. @entity1 were asked about duration of postoperative @entity490 , and if @entity158 was still present to describe the frequency and intensity of @entity158 and its impact on daily life. The questionnaire also included questions about the Caesarean section and about @entity158 problems elsewhere. RESULTS: A total of 220 @entity1 (90.2%) answered the questionnaire. The mean follow-up time was 10.2 months (range 6-17.6). @entity282 resolved in most @entity1 within 3 months but 27 @entity1 (12.3%) still had @entity158 at the time of the interview. No @entity1 had @entity158 , but in 13 of 27 @entity1 (5.9%) @entity158 was present daily or almost daily. @entity1 with persistent @entity158 (n = 27) had more often undergone general than spinal anaesthesia for the Caesarean section. Frequencies of @entity158 problems elsewhere and recalls of severe @entity282 were also higher among @entity1 with persistent @entity158 . CONCLUSION: @entity1118 after Caesarean section seems to be a significant problem in at least 5.9% of @entity1 .

title: XXXX following Caesarean section.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal scar pain']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'constant pain']

entities_list: @entity169 :: ('MESH:D006552', 'Disease') :: ['inguinal hernia repair']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['acute postoperative pain', 'Chronic postoperative pain', 'Postoperative pain']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['Chronic pain', 'chronic pain']

answer: @entity1118 :: (MESH:D059350,Disease) :: ['Chronic pain']


abstract: BACKGROUND: Childhood @entity458 (CSA) survivors deal with complex mental, physical and relationship problems in adulthood which negatively affects their well-being and health. The aim of the present paper was to present a description of the Wellness-Program for female CSA survivors, the participating @entity1 's evaluation of the different therapies in the program as well as a qualitative study on their experience of the program's effects on their life, health and well-being. METHOD: The Wellness-Program lasted for 10  weeks with organised schedule 20  hours per week. A team of health professionals used a holistic approach and provided traditional and complementary individual and group therapy focusing on both mind and body. In-depth phenomenological interviews with ten @entity1 , 22-53  years old, were conducted 1  week before and 1  week after the program as well as 15  months later. Data collection and data analysis were guided by the Vancouver School of doing phenomenology. RESULTS: Prior to participating in the program, the @entity1 were unable to work or attend school, were on disability allowance, were socially isolated and had complex health problems. After the Wellness-Program, all the @entity1 , except one, were back to work, school or in further rehabilitation. Furthermore, the in-depth interviews showed that their health and well-being, personal life and relationship with partners, family and friends improved. They felt empowered, more in control and had developed increased trust towards others. Six themes were constructed from the in-depth interviews. They were: feeling totally lost, releasing experiences, developing trusting relationships, gaining control, experiencing positive changes in physical and mental health and, finally, feeling of empowerment. The overriding theme of the study was personal resurrection. CONCLUSIONS: The Wellness-Program contributed considerably to improved health and well-being of the @entity1 . However, further assessment of the program is recommended before making it available within the healthcare system.

title: Personal resurrection: female childhood XXXX ' experience of the Wellness-Program.

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['sexual abuse']

answer: @entity458 :: (MESH:D020018,Disease) :: ['sexual abuse survivors']


abstract: @entity662 is a hallmark symptom in @entity1 with unstable @entity951 (UAP). However, little is known regarding the prevalence of an atypical presentation among these @entity1 and its relation to subsequent care. We examined the medical records of 4,167 randomly sampled Medicare @entity1 hospitalized with unstable @entity951 at 22 Alabama hospitals between 1993 and 1999. We defined typical presentation as (1) @entity662 located substernally in the left or right chest, or (2) @entity662 characterized as squeezing, tightness, @entity158 , crushing, arm discomfort, dullness, @entity27915 , @entity11728 , pressure, or @entity158 aggravated by exercise or relieved with rest or @entity1242 . Atypical presentation was defined as confirmed UAP without typical presentation. Among @entity1 with confirmed UAP, 51.7% had atypical presentations. The most frequent symptoms associated with atypical presentation were @entity1353 (69.4%), @entity390 (37.7%), diaphoresis (25.2%), @entity1163 (10.6%), or @entity158 in the arms (11.5%), epigastrium (8.1%), shoulder (7.4%), or neck (5.9%). Independent predictors of atypical presentation for @entity1 with UAP were older age (odds ratio 1.09, 95% confidence interval 1.01 to 1.17/decade), history of @entity303 (odds ratio 1.49, 95% confidence interval 1.10 to 2.03), and absence of prior @entity583 , @entity1007 , or family history of @entity299 . @entity1 with atypical presentation received @entity117 , heparin, and beta-blocker therapy less aggressively, but there was no difference in mortality. Thus, over half of Medicare @entity1 with confirmed UAP had "atypical" presentations. National educational initiatives may need to redefine the classic presentation of UAP to include atypical presentations to ensure appropriate quality of care.

title: Atypical presentations among Medicare beneficiaries with unstable XXXX .

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['Chest pain', 'chest pain']

entities_list: @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia']

entities_list: @entity1242 :: ('MESH:D005996', 'Chemical') :: ['nitroglycerin']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris', 'angina']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity951 :: (MESH:D000787,Disease) :: ['angina pectoris']


abstract: The association between users of combined oral contraceptives and depot- @entity11796 ( @entity12135 ) for contraception and @entity79 ( @entity79 ) has been controversial because of variations among studies. Like other studies, this cross-sectional study compares @entity79 in users of combined oral contraceptives and @entity12135 with that in nonusers. Unlike previous studies, we defined long-term use as >2 years, and we measured more bone sites than previous studies including lumbar spines, femurs, and forearms. The study group consisted of 59 @entity1 aged 30 years to 34 years who had been using combined oral contraceptives for 57.36 +/- 27.02 months with a minimum period of 24 months, 34 @entity1 of the same age who had been using @entity12135 as contraceptive for 55.76 +/- 35.31 months, and 62 @entity1 of the same age who had not used any @entity134 hormonal contraceptives for more than 6 months. @entity79 was measured by dual energy photon absorptiometer at lumbar spine 2-4, neck of femur, Ward's triangle of femur, greater trochanter of femur, ultradistal radius, and distal ulnar, respectively. Age, body mass index, and lifestyles of both groups were matched with nonusers. Mean @entity79 at lumbar spine ( @entity2586 ) in the @entity12135 users was significantly lower than in the controls (1.031 +/- 0.090 vs. 1.096 +/- 0.116, p = 0.007). There were no significant differences in @entity79 values at bone sites other than lumbar spine between @entity12135 users and the controls. There were no significant differences in @entity79 values at all bone sites between combined oral contraceptives users and the controls. We conclude that combined oral contraceptives are not associated with changes in values of @entity79 , while @entity12135 is associated with decreased @entity79 only at lumbar spine. We comment that @entity134 hormonal contraceptives are safe to use for long-term contraception regarding bone mass effects.

title: Bone mineral density at various anatomic bone sites in @entity1 receiving combined oral contraceptives and depot- XXXX for contraception.

entities_list: @entity11796 :: ('MESH:D017258', 'Chemical') :: ['medroxyprogesterone acetate']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

answer: @entity11796 :: (MESH:D017258,Chemical) :: ['medroxyprogesterone acetate']


abstract: The association between users of combined oral contraceptives and depot- @entity11796 ( @entity12135 ) for contraception and @entity79 ( @entity79 ) has been controversial because of variations among studies. Like other studies, this cross-sectional study compares @entity79 in users of combined oral contraceptives and @entity12135 with that in nonusers. Unlike previous studies, we defined long-term use as >2 years, and we measured more bone sites than previous studies including lumbar spines, femurs, and forearms. The study group consisted of 59 @entity1 aged 30 years to 34 years who had been using combined oral contraceptives for 57.36 +/- 27.02 months with a minimum period of 24 months, 34 @entity1 of the same age who had been using @entity12135 as contraceptive for 55.76 +/- 35.31 months, and 62 @entity1 of the same age who had not used any @entity134 hormonal contraceptives for more than 6 months. @entity79 was measured by dual energy photon absorptiometer at lumbar spine 2-4, neck of femur, Ward's triangle of femur, greater trochanter of femur, ultradistal radius, and distal ulnar, respectively. Age, body mass index, and lifestyles of both groups were matched with nonusers. Mean @entity79 at lumbar spine ( @entity2586 ) in the @entity12135 users was significantly lower than in the controls (1.031 +/- 0.090 vs. 1.096 +/- 0.116, p = 0.007). There were no significant differences in @entity79 values at bone sites other than lumbar spine between @entity12135 users and the controls. There were no significant differences in @entity79 values at all bone sites between combined oral contraceptives users and the controls. We conclude that combined oral contraceptives are not associated with changes in values of @entity79 , while @entity12135 is associated with decreased @entity79 only at lumbar spine. We comment that @entity134 hormonal contraceptives are safe to use for long-term contraception regarding bone mass effects.

title: Bone mineral density at various anatomic bone sites in XXXX receiving combined oral contraceptives and depot- @entity11796 for contraception.

answer: @entity1 :: (9606,Species) :: ['women']


abstract: @entity438 ( @entity438 ) are rare and are usually atherosclerotic and/or related to pregnancy. Because pregnancy is the most important predisposing factor, the strong predilection of @entity438 for @entity1 is not surprising. The authors report a case of @entity1756 in a @entity1 with chronic @entity788 as the predisposing factor. A 56-year-old @entity1 with @entity490 and @entity6552 was resuscitated and underwent endoscopy, but he died 18 hours later of massive @entity6552 before definitive surgery could be carried out. At autopsy, there was chronic @entity788 with @entity82 tethering the tail of the pancreas, spleen, and posterior wall of the stomach together. The @entity438 was indented into the posterior wall of the stomach, into which it had ruptured from without. He also had alcoholic @entity82 but no esophageal varices or conventional gastric ulcers. Other important predisposing factors such as @entity1661 , @entity884 , @entity11657 , and @entity1347 were absent. Histologic examination confirmed the @entity397 of the @entity438 . The @entity438 had Monckeberg medial calcinosis but little evidence of @entity731 . The well-documented complications of @entity1689 include @entity1457 , abscess, @entity9727 . This report describes the rare complication of @entity1756 , which may be fatal.

title: Fatal splenic arterial aneurysmal @entity397 associated with chronic XXXX .

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis', 'fibrous adhesions']

entities_list: @entity6552 :: ('MESH:D006396', 'Disease') :: ['hematemesis']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['Splenic arterial aneurysms', 'SAA']

entities_list: @entity1347 :: ('MESH:C537775', 'Disease') :: ['segmental medial arteriopathy']

entities_list: @entity1661 :: ('MESH:D000008', 'Disease') :: ['abdominal trauma']

entities_list: @entity1689 :: ('MESH:D050500', 'Disease') :: ['acute and chronic pancreatitis']

entities_list: @entity9727 :: ('MESH:D004380', 'Disease') :: ['pseudocyst formation, and duodenal obstruction']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['infective endocarditis']

entities_list: @entity11657 :: ('MESH:D010488', 'Disease') :: ['polyarteritis nodosa']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity1756 :: ('MESH:D017542', 'Disease') :: ['SAA rupture']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatitis']


abstract: @entity438 ( @entity438 ) are rare and are usually atherosclerotic and/or related to pregnancy. Because pregnancy is the most important predisposing factor, the strong predilection of @entity438 for @entity1 is not surprising. The authors report a case of @entity1756 in a @entity1 with chronic @entity788 as the predisposing factor. A 56-year-old @entity1 with @entity490 and @entity6552 was resuscitated and underwent endoscopy, but he died 18 hours later of massive @entity6552 before definitive surgery could be carried out. At autopsy, there was chronic @entity788 with @entity82 tethering the tail of the pancreas, spleen, and posterior wall of the stomach together. The @entity438 was indented into the posterior wall of the stomach, into which it had ruptured from without. He also had alcoholic @entity82 but no esophageal varices or conventional gastric ulcers. Other important predisposing factors such as @entity1661 , @entity884 , @entity11657 , and @entity1347 were absent. Histologic examination confirmed the @entity397 of the @entity438 . The @entity438 had Monckeberg medial calcinosis but little evidence of @entity731 . The well-documented complications of @entity1689 include @entity1457 , abscess, @entity9727 . This report describes the rare complication of @entity1756 , which may be fatal.

title: Fatal splenic arterial aneurysmal XXXX associated with chronic @entity788 .

answer: @entity397 :: (MESH:D012421,Disease) :: ['rupture']


abstract: BACKGROUND: We examined the influences of a moderate intake level of three types of alcoholic beverages--beer, whisky, and Shochu (Japanese distilled liquor)--on @entity10043 and @entity1735 metabolism and excretion in healthy male volunteers, concerning (1) the extent of contribution of @entity10043 bodies contained in beer to @entity414 metabolism and (2) a comparison between two types of distilled spirits with (whisky) and without (Shochu) aging in oak wood barrel storage. METHODS: Three sets of studies were conducted in which 10 to 13 healthy adult @entity1 were instructed to drink three types of alcoholic beverages at a slightly higher level (0.8 ml of @entity1068 equivalent/kg body weight) than moderate drinking (approximately 30.4 ml or less for @entity1 ). A low @entity10043 beer was test-manufactured by treating nucleosides that were contained in wort and remained in beer with @entity10043 @entity2353 phosphorylase derived from Ochrobacterium anthropi, thereby converting them into corresponding @entity10043 bases that were easily assimilated by beer @entity375 . RESULTS: Although beer intake enhanced the level of serum @entity414 by 13.6%, blood @entity413 by 26.7%, and insulin level by 5.1-fold, drinking a moderate level of distilled liquor (whisky, Shochu) did not increase the serum @entity414 level or the other two parameters. The serum @entity414 level observed after drinking beer with a @entity10043 body concentration reduced by 28% (68% in @entity2642 and @entity10043 bases) was almost identical to the level observed after drinking regular beer. Whisky has been found to have a property that decreases the serum @entity414 level. Excretion of @entity414 from blood is increased by 27% after drinking whisky. CONCLUSIONS: Moderate drinking of distilled liquors did not enhance serum @entity414 level, blood @entity413 , or insulin level in healthy male subjects. Increased serum @entity414 after beer intake could not be explained mostly with their @entity10043 body congeners. Whisky showed the eliminative property in serum @entity414 through excretion of it from blood to urine. At a moderate drinking level, beer and whisky have different effects on @entity10043 metabolism or excretion.

title: Influence of moderate drinking on XXXX and @entity1735 metabolism.

entities_list: @entity2642 :: ('MESH:D009705', 'Chemical') :: ['nucleosides']

entities_list: @entity2353 :: ('CHEBI:33838', 'Chemical') :: ['nucleoside']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']

answer: @entity10043 :: (MESH:C030985,Chemical) :: ['purine']


abstract: BACKGROUND: We examined the influences of a moderate intake level of three types of alcoholic beverages--beer, whisky, and Shochu (Japanese distilled liquor)--on @entity10043 and @entity1735 metabolism and excretion in healthy male volunteers, concerning (1) the extent of contribution of @entity10043 bodies contained in beer to @entity414 metabolism and (2) a comparison between two types of distilled spirits with (whisky) and without (Shochu) aging in oak wood barrel storage. METHODS: Three sets of studies were conducted in which 10 to 13 healthy adult @entity1 were instructed to drink three types of alcoholic beverages at a slightly higher level (0.8 ml of @entity1068 equivalent/kg body weight) than moderate drinking (approximately 30.4 ml or less for @entity1 ). A low @entity10043 beer was test-manufactured by treating nucleosides that were contained in wort and remained in beer with @entity10043 @entity2353 phosphorylase derived from Ochrobacterium anthropi, thereby converting them into corresponding @entity10043 bases that were easily assimilated by beer @entity375 . RESULTS: Although beer intake enhanced the level of serum @entity414 by 13.6%, blood @entity413 by 26.7%, and insulin level by 5.1-fold, drinking a moderate level of distilled liquor (whisky, Shochu) did not increase the serum @entity414 level or the other two parameters. The serum @entity414 level observed after drinking beer with a @entity10043 body concentration reduced by 28% (68% in @entity2642 and @entity10043 bases) was almost identical to the level observed after drinking regular beer. Whisky has been found to have a property that decreases the serum @entity414 level. Excretion of @entity414 from blood is increased by 27% after drinking whisky. CONCLUSIONS: Moderate drinking of distilled liquors did not enhance serum @entity414 level, blood @entity413 , or insulin level in healthy male subjects. Increased serum @entity414 after beer intake could not be explained mostly with their @entity10043 body congeners. Whisky showed the eliminative property in serum @entity414 through excretion of it from blood to urine. At a moderate drinking level, beer and whisky have different effects on @entity10043 metabolism or excretion.

title: Influence of moderate drinking on @entity10043 and XXXX metabolism.

answer: @entity1735 :: (CHEBI:16646,Chemical) :: ['carbohydrate']


abstract: To investigate the contribution of cytokines, proinflammatory @entity1505 and inhibitory @entity1810 , to @entity1566 ( @entity1566 ) in a @entity35 model, two studies were performed using adult @entity35 which were injured at T9/T10. In the first study, @entity35 were sacrificed at 1, 6, 24, 96 and 168 h after @entity1566 for immunocytochemistry of coronal sections for the presence of mononuclear phagocytes, astrocytes, @entity1505 and @entity1810 , among other markers. From intervening frozen sections, RNA was extracted for semiquantitative polymerase chain reaction (RT-PCR) analysis of @entity1505 and @entity1810 . In the second experiment, @entity35 were treated with intravenous @entity1810 30 min after injury and sacrificed at 6 and 48 h after injury. Spinal cord sections were immunocytochemically stained and RNA extracted for semiquantitative PCR as mentioned above, as well as quantitation of lesion volume. There were increases in mononuclear phagocytes and astrocytes, as early as 1 h after @entity1566 , with steady progression over 168 h after injury. @entity1505 and @entity1810 was produced locally by mononuclear phagocytes and astrocytes. There was an 18-h delay in peak mRNA production of @entity1810 compared to @entity1505 . The treatment of @entity1566 @entity35 with @entity1810 reduced lesion volume by 50% at 48 h and this was associated with decreased accumulation of mononuclear phagocytes in and around the injury site. This reduction of mononuclear phagocyte numbers around the site of @entity130 would reduce their contribution to secondary injury.

title: Treatment of spinal cord impact injury in the XXXX with transforming growth factor-beta.

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats', 'rats']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'SCI']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: The aim of the present study was to evaluate both estrogenic effects in directly NP-exposed sexually mature @entity5660 and possible transgenerational effects in the offspring of exposed fish. Four months prior to spawning, adult @entity5660 of both sexes were exposed intermittently to NP concentrations of 1 and 10 microg/l. At the end of the exposure period, which coincided with the beginning of spawning time, @entity38901 levels in the plasma of adult male rainbow showed a significant increase compared to the control group. After exposure to 10 microg NP/l reproduction was impaired as indicated by significantly reduced hatching rates. Histological examination of the testicular tissue of NP-exposed individuals revealed no morphological differences from the controls. In the offspring, @entity38901 levels of male individuals were not affected, whereas in females they were significantly higher than in the control progeny. The histological examination revealed no alteration in sex ratios. In single cases, intersex occurred in both male and female offspring of exposed fish. The analysis of sex @entity134 levels revealed a two-fold increase of @entity53 in the plasma of male offspring and a 13-fold elevation of @entity251 in the plasma of female progeny. The present findings indicate that NP, in an environmentally relevant concentration range, acts as a weak @entity172 in directly exposed adult male @entity5660 as indicated by elevated plasma @entity38901 levels. Reproduction success was reduced as indicated by decreased hatching rates. Hormonal imbalances detected in the offspring of exposed fish indicate a transgenerational effect mediated by the endocrine system.

title: How estrogenic is nonylphenol? A transgenerational study using XXXX ( @entity5660 ) as a test organism.

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity5660 :: ('8022', 'Species') :: ['rainbow trout']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

answer: @entity5660 :: (8022,Species) :: ['rainbow trout']


abstract: The aim of the present study was to evaluate both estrogenic effects in directly NP-exposed sexually mature @entity5660 and possible transgenerational effects in the offspring of exposed fish. Four months prior to spawning, adult @entity5660 of both sexes were exposed intermittently to NP concentrations of 1 and 10 microg/l. At the end of the exposure period, which coincided with the beginning of spawning time, @entity38901 levels in the plasma of adult male rainbow showed a significant increase compared to the control group. After exposure to 10 microg NP/l reproduction was impaired as indicated by significantly reduced hatching rates. Histological examination of the testicular tissue of NP-exposed individuals revealed no morphological differences from the controls. In the offspring, @entity38901 levels of male individuals were not affected, whereas in females they were significantly higher than in the control progeny. The histological examination revealed no alteration in sex ratios. In single cases, intersex occurred in both male and female offspring of exposed fish. The analysis of sex @entity134 levels revealed a two-fold increase of @entity53 in the plasma of male offspring and a 13-fold elevation of @entity251 in the plasma of female progeny. The present findings indicate that NP, in an environmentally relevant concentration range, acts as a weak @entity172 in directly exposed adult male @entity5660 as indicated by elevated plasma @entity38901 levels. Reproduction success was reduced as indicated by decreased hatching rates. Hormonal imbalances detected in the offspring of exposed fish indicate a transgenerational effect mediated by the endocrine system.

title: How estrogenic is nonylphenol? A transgenerational study using @entity5660 ( XXXX ) as a test organism.

answer: @entity5660 :: (8022,Species) :: ['Oncorhynchus mykiss']


abstract: PURPOSE: In previous studies in which in vivo confocal microscopy (CM) was used, quantifiable differences were identified in the corneal epithelium and stroma for surfactants producing different degrees of @entity146 . In the present study, in vivo confocal microscopy was used to determine area and depth of the initial corneal changes, and the correlation of the data to cell death was characterized by ex vivo live-dead assay. METHODS: In four groups of @entity95 (12 animals each), 10 microl surfactants known to produce slight, mild, moderate, or severe @entity146 was applied to the central @entity735 ; 4 untreated @entity95 served as controls. Measurements of group total mean epithelial thickness, epithelial cell area, and depth of keratocyte loss in four corneal regions were made by in vivo CM in 6 @entity95 of each group and in 4 control animals at 3 hours and in the remaining @entity95 at 3 hours and 1 day. Corneas were then removed and fixed for conventional histologic examination (two eyes/treatment/group), or regions were excised and placed in culture media containing 2 microM @entity10857 ( @entity10857 ) and 4 microM @entity5611 homodimer. Using laser scanning CM, the number of dead epithelial or stromal cells in a 300 x 300 x 170 microm (in the x, y, and z axes, respectively) volume of the @entity267 was determined. RESULTS: Confocal microscopy showed that application of the slight irritant resulted in decreased epithelial thickness at 3 hours (41.2+/-2.6 microm in treated eyes versus 43.6+/-3 microm in control eyes; n=6 and 4, respectively) and a significant decrease (P < 0.001) in epithelial cell size (630+/-203 microm2 versus 1427.2+/-90.7 microm2). On day 1, mild, moderate, and severe @entity146 caused complete loss of epithelium and disappearance of keratocytes to a depth of 30.8+/-10.7 microm, 47.2+/-10.4 microm, and 764.6+/-159.6 microm (n=6, 5, and 6), respectively. At 3 hours, live-dead assay detected more dead epithelial cells as a percentage of total surface cells (49.2+/-4.5% in slightly @entity146 versus 20.9+/-3.2% in control eyes), significantly correlating with the measurement by in vivo CM of average epithelial cell size in each eye (r=-0.96; P < 0.005). On day 1, mild and moderate @entity146 showed increasing stromal cell death from 9.8+/-16.2 cells to 36.4+/-17.7 cells, which significantly correlated with the depth of stromal injury determined by in vivo CM (r=0.79; P < 0.00001). No surviving keratocytes were detected in severely @entity146 . CONCLUSIONS: The data support the hypothesis that differences in surfactant-induced @entity146 are directly related to area and depth of acute @entity267 .

title: Area and depth of surfactant-induced XXXX correlates with cell death.

entities_list: @entity267 :: ('MESH:D065306', 'Disease') :: ['cornea', 'corneal injury']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['ocular irritation', 'irritants', 'irritated eyes', 'irritation']

entities_list: @entity5611 :: ('MESH:D004996', 'Chemical') :: ['ethidium']

entities_list: @entity10857 :: ('MESH:C085925', 'Chemical') :: ['calcein-acetoxymethyl ester', 'calcein-AM']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['cornea of one eye']

answer: @entity267 :: (MESH:D065306,Disease) :: ['corneal injury']


abstract: OBJECTIVES: @entity1 with solid @entity5 are at greatest risk for dying from their @entity5 in the five years following diagnosis. For most @entity5 , @entity204 from other @entity102 begin to exceed those from @entity5 at some point. As little is known about the causes of @entity204 among long-term survivors of @entity43 , we examined causes of @entity204 by years from diagnosis. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify @entity1 diagnosed with @entity43 between 1988 and 2012. We compared causes of @entity204 by stage, age, and interval time after diagnosis. RESULTS: A total of 67,385 @entity1 were identified. For stage I @entity5 , 13.6% (CI, 13.0-14.2%) died from @entity43 , 4.2% (CI, 3.8-4.5%) from @entity65 , 3.6% (CI, 3.3-3.9%) from other causes and 2.6% (CI, 2.4-2.9%) from other @entity5 ; @entity43 was the leading cause of @entity204 until 7years after diagnosis after which time @entity204 are more frequently due to other causes. For those with @entity5 , 67.8% (CI, 67.3-68.2%) died from @entity43 , 2.8% (CI, 2.6-2.9%) from other causes, 2.3% (CI, 2.2-2.4%) from @entity65 and 1.9% (CI, 1.7-2.0%) from other @entity5 ; @entity43 was the most frequent cause of @entity204 in years 1-15 after which time @entity204 were more commonly due to other causes. CONCLUSIONS: The probability of dying from @entity43 decreases with time. @entity43 remains the most common cause of @entity204 for 15years after diagnosis in @entity1 with @entity5 .

title: Long-term mortality among @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'Ovarian cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'stage III-IV tumors', 'cancers', 'cancer', 'neoplasms', 'malignancies']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic diseases']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity43 :: (MESH:D010051,Disease) :: ['epithelial ovarian cancer']


abstract: OBJECTIVES: @entity1 with solid @entity5 are at greatest risk for dying from their @entity5 in the five years following diagnosis. For most @entity5 , @entity204 from other @entity102 begin to exceed those from @entity5 at some point. As little is known about the causes of @entity204 among long-term survivors of @entity43 , we examined causes of @entity204 by years from diagnosis. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify @entity1 diagnosed with @entity43 between 1988 and 2012. We compared causes of @entity204 by stage, age, and interval time after diagnosis. RESULTS: A total of 67,385 @entity1 were identified. For stage I @entity5 , 13.6% (CI, 13.0-14.2%) died from @entity43 , 4.2% (CI, 3.8-4.5%) from @entity65 , 3.6% (CI, 3.3-3.9%) from other causes and 2.6% (CI, 2.4-2.9%) from other @entity5 ; @entity43 was the leading cause of @entity204 until 7years after diagnosis after which time @entity204 are more frequently due to other causes. For those with @entity5 , 67.8% (CI, 67.3-68.2%) died from @entity43 , 2.8% (CI, 2.6-2.9%) from other causes, 2.3% (CI, 2.2-2.4%) from @entity65 and 1.9% (CI, 1.7-2.0%) from other @entity5 ; @entity43 was the most frequent cause of @entity204 in years 1-15 after which time @entity204 were more commonly due to other causes. CONCLUSIONS: The probability of dying from @entity43 decreases with time. @entity43 remains the most common cause of @entity204 for 15years after diagnosis in @entity1 with @entity5 .

title: Long-term mortality among XXXX with @entity43 .

answer: @entity1 :: (9606,Species) :: ['women']


abstract: PURPOSE: We describe 2 @entity1 , aged 19 years, who experienced a rolandic @entity410 at ages 4 and 5, respectively, together with the interictal EEG features of @entity1654 ( @entity1654 ). In adolescence both @entity1 developed photosensitive occipital @entity410 accompanied by spontaneous and photic-induced occipital EEG paroxysms. METHODS: We have been following 33 @entity1 with a history of @entity1654 , between ages 12 and 28 years (mean 17 years). Twenty-one of these @entity1 had experienced their last rolandic @entity410 before the age of 10 years and 9 of them had been without treatment since age 11 or earlier. In 2 of these 9 @entity1 , other types of @entity410 recurred after remission of @entity1654 . Clinical, EEG, and evoked potential findings on these 2 @entity1 are presented. RESULTS: After having experienced @entity1654 , both @entity1 suffered partial @entity410 from age 12, with @entity1833 , @entity227 , slow head turning, @entity158 , epigastric discomfort, unresponsiveness, and @entity391 . @entity410 onset was related to watching TV or exposure to bright light. EEG showed interictal occipital spikes, and a photoparoxysmal response limited to the occipital lobes. Visual evoked potentials were greatly increased in amplitude. One @entity1 had two @entity227 and remained @entity410 free after 4 years of follow-up, while the other had @entity410 controlled by an association of @entity1092 and @entity2049 . CONCLUSIONS: Clinical and neurophysiological characteristics suggest that these two @entity1 may have presented different age-related expressions within the spectrum of a benign @entity410 susceptibility syndrome rather than sharply distinct @entity302 .

title: Adolescent onset of idiopathic photosensitive occipital epilepsy after remission of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'girls']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'Seizure']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual attacks only', 'visual blurring']

entities_list: @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproate']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['elementary visual hallucinations']

entities_list: @entity1654 :: ('MESH:D019305', 'Disease') :: ['benign rolandic epilepsy', 'BRE']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy syndromes']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['cephalic pain']

entities_list: @entity2049 :: ('MESH:D002220', 'Chemical') :: ['carbamazepine']

answer: @entity1654 :: (MESH:D019305,Disease) :: ['benign rolandic epilepsy']


abstract: PURPOSE: The electroencephalographic hallmark of benign childhood @entity302 with centrotemporal spikes (BECTS, or @entity1654 ) are characteristically shaped centrotemporal spikes and sharp waves ( @entity923 ). This EEG trait, but not BECTS itself, has been reported to follow an autosomal dominant mode of inheritance with incomplete penetrance and age @entity734 . @entity923 therefore represents a neurobiologic marker for the increased risk of developing BECTS. @entity11529 ( @entity11529 ) like BECTS is an idiopathic age-dependent @entity302 with a benign course. Observations of @entity410 and BECTS in the same individual are well documented. @entity410 with benign course were found in increased numbers in a series of @entity923 carriers. Two genetic loci, @entity15748 and @entity15749 , have been mapped in families with @entity11529 , making these two loci strong candidates for the @entity923 trait underlying BECTS. The aim of this study was to determine whether these two @entity302 are @entity74 . METHODS: Linkage analysis was performed in 12 families with probands with BECTS and one or more relatives with @entity923 in the EEG with or without BECTS by using polymorphic DNA markers. RESULTS: Assuming an autosomal mode of inheritance with penetrances of 0.9 and 0.45, respectively, both loci were consistently excluded. CONCLUSIONS: The @entity923 trait and @entity15748 and @entity15749 segregate independently. BECTS and @entity11529 therefore appear to be genetically distinct entities. @entity410 may be a underrecognized symptom of the @entity923 trait itself.

title: Benign childhood @entity302 with centrotemporal spikes and electroencephalography trait are not linked to XXXX and @entity15749 of @entity11529 .

entities_list: @entity11529 :: ('MESH:D020936', 'Disease') :: ['BNFC', 'Benign neonatal familial convulsions']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['Benign neonatal seizures', 'benign neonatal seizures', 'Neonatal seizures']

entities_list: @entity1654 :: ('MESH:D019305', 'Disease') :: ['rolandic epilepsy']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy syndromes', 'epilepsy']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['allelic disorders']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['dependence']

answer: @entity15748 :: (3785,Gene) :: ['EBN1']


abstract: PURPOSE: The electroencephalographic hallmark of benign childhood @entity302 with centrotemporal spikes (BECTS, or @entity1654 ) are characteristically shaped centrotemporal spikes and sharp waves ( @entity923 ). This EEG trait, but not BECTS itself, has been reported to follow an autosomal dominant mode of inheritance with incomplete penetrance and age @entity734 . @entity923 therefore represents a neurobiologic marker for the increased risk of developing BECTS. @entity11529 ( @entity11529 ) like BECTS is an idiopathic age-dependent @entity302 with a benign course. Observations of @entity410 and BECTS in the same individual are well documented. @entity410 with benign course were found in increased numbers in a series of @entity923 carriers. Two genetic loci, @entity15748 and @entity15749 , have been mapped in families with @entity11529 , making these two loci strong candidates for the @entity923 trait underlying BECTS. The aim of this study was to determine whether these two @entity302 are @entity74 . METHODS: Linkage analysis was performed in 12 families with probands with BECTS and one or more relatives with @entity923 in the EEG with or without BECTS by using polymorphic DNA markers. RESULTS: Assuming an autosomal mode of inheritance with penetrances of 0.9 and 0.45, respectively, both loci were consistently excluded. CONCLUSIONS: The @entity923 trait and @entity15748 and @entity15749 segregate independently. BECTS and @entity11529 therefore appear to be genetically distinct entities. @entity410 may be a underrecognized symptom of the @entity923 trait itself.

title: Benign childhood XXXX with centrotemporal spikes and electroencephalography trait are not linked to @entity15748 and @entity15749 of @entity11529 .

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: PURPOSE: The electroencephalographic hallmark of benign childhood @entity302 with centrotemporal spikes (BECTS, or @entity1654 ) are characteristically shaped centrotemporal spikes and sharp waves ( @entity923 ). This EEG trait, but not BECTS itself, has been reported to follow an autosomal dominant mode of inheritance with incomplete penetrance and age @entity734 . @entity923 therefore represents a neurobiologic marker for the increased risk of developing BECTS. @entity11529 ( @entity11529 ) like BECTS is an idiopathic age-dependent @entity302 with a benign course. Observations of @entity410 and BECTS in the same individual are well documented. @entity410 with benign course were found in increased numbers in a series of @entity923 carriers. Two genetic loci, @entity15748 and @entity15749 , have been mapped in families with @entity11529 , making these two loci strong candidates for the @entity923 trait underlying BECTS. The aim of this study was to determine whether these two @entity302 are @entity74 . METHODS: Linkage analysis was performed in 12 families with probands with BECTS and one or more relatives with @entity923 in the EEG with or without BECTS by using polymorphic DNA markers. RESULTS: Assuming an autosomal mode of inheritance with penetrances of 0.9 and 0.45, respectively, both loci were consistently excluded. CONCLUSIONS: The @entity923 trait and @entity15748 and @entity15749 segregate independently. BECTS and @entity11529 therefore appear to be genetically distinct entities. @entity410 may be a underrecognized symptom of the @entity923 trait itself.

title: Benign childhood @entity302 with centrotemporal spikes and electroencephalography trait are not linked to @entity15748 and XXXX of @entity11529 .

answer: @entity15749 :: (3786,Gene) :: ['EBN2']


abstract: PURPOSE: The electroencephalographic hallmark of benign childhood @entity302 with centrotemporal spikes (BECTS, or @entity1654 ) are characteristically shaped centrotemporal spikes and sharp waves ( @entity923 ). This EEG trait, but not BECTS itself, has been reported to follow an autosomal dominant mode of inheritance with incomplete penetrance and age @entity734 . @entity923 therefore represents a neurobiologic marker for the increased risk of developing BECTS. @entity11529 ( @entity11529 ) like BECTS is an idiopathic age-dependent @entity302 with a benign course. Observations of @entity410 and BECTS in the same individual are well documented. @entity410 with benign course were found in increased numbers in a series of @entity923 carriers. Two genetic loci, @entity15748 and @entity15749 , have been mapped in families with @entity11529 , making these two loci strong candidates for the @entity923 trait underlying BECTS. The aim of this study was to determine whether these two @entity302 are @entity74 . METHODS: Linkage analysis was performed in 12 families with probands with BECTS and one or more relatives with @entity923 in the EEG with or without BECTS by using polymorphic DNA markers. RESULTS: Assuming an autosomal mode of inheritance with penetrances of 0.9 and 0.45, respectively, both loci were consistently excluded. CONCLUSIONS: The @entity923 trait and @entity15748 and @entity15749 segregate independently. BECTS and @entity11529 therefore appear to be genetically distinct entities. @entity410 may be a underrecognized symptom of the @entity923 trait itself.

title: Benign childhood @entity302 with centrotemporal spikes and electroencephalography trait are not linked to @entity15748 and @entity15749 of XXXX .

answer: @entity11529 :: (MESH:D020936,Disease) :: ['benign neonatal familial convulsions']


abstract: PURPOSE: We wished to determine whether continuous EEG source imaging can predict the location of @entity410 onset with sublobar accuracy in @entity1315 ( @entity1315 ). METHODS: We retrospectively analyzed the earliest scalp ictal rhythms, recorded with 23- to 27-channel EEG, in 40 @entity1 with intractable @entity1315 . A continuous source analysis technique with multiple fixed dipoles (Focus 1.1) decomposed the EEG into source components representing the activity of major cortical sublobar surfaces. For the temporal lobe, these were basal, anterior tip, anterolateral, and posterolateral cortex. Ictal EEG onset was categorized according to its most prominent and leading source component. All @entity1 underwent intracranial EEG studies before @entity302 surgery, and all had a successful surgical outcome (follow-up >1 year). RESULTS: Most @entity1 with ictal rhythms having a predominant basal source component had hippocampal-onset @entity410 , whereas those with @entity410 with prominent lateral source activity had predominantly temporal neocortical @entity410 origins. @entity410 with a prominent anterior temporal tip source component mostly had onset in entorhinal cortex. @entity410 in some @entity1 had several equally large and nearly synchronous source components. These @entity410 , which could be modeled equally well by a single oblique dipole, had onset predominantly in either entorhinal or lateral temporal cortex. CONCLUSIONS: Multiple fixed dipole analysis of scalp EEG can provide information about the origin of temporal lobe @entity410 that is useful in presurgical planning. In particular, it can reliably distinguish @entity410 of mesial temporal origin from those of lateral temporal origin.

title: Continuous source imaging of scalp ictal rhythms in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'Seizures', 'seizures']

entities_list: @entity1315 :: ('MESH:D004833', 'Disease') :: ['TLE', 'temporal lobe epilepsy']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

answer: @entity1315 :: (MESH:D004833,Disease) :: ['temporal lobe epilepsy']


abstract: INTRODUCTION: The evidence on the effectiveness of rehabilitation in @entity2 @entity1 is limited. Whole body vibration (WBV) has been proposed as an alternative to conventional resistance training (CRT). METHODS: We investigated the effect of @entity34 ( @entity34 ) and of two rehabilitation programmes in @entity2 @entity1 . The primary endpoint was a change in 6-min walking distance (6MWD) after rehabilitation. @entity1 were randomised after @entity34 to either CRT, WBVT or standard follow-up (CON). @entity1 were evaluated before, after @entity34 and after 12 weeks of intervention. RESULTS: Of 121 included @entity1 , 70 were randomised to either CON (24), CRT (24) or WBVT (22). After @entity34 , 6MWD decreased with a mean of 38m (95% CI 22-54) and increased with a mean of 95m (95% CI 58-132) in CRT (p<0.0001), 37m (95% CI -1-76) in WBVT (p=0.06) and 1m (95% CI -34-36) in CON (p=0.95), respectively. Surgical treatment, magnitude of decrease in 6MWD by @entity34 and allocation to either CRT or WBVT were prognostic for reaching the minimally clinically important difference of 54m increase in 6MWD after intervention. CONCLUSIONS: @entity34 of @entity2 significantly impairs @entity1 ' exercise capacity. CRT significantly improves and restores functional exercise capacity, whereas WBVT does not fully substitute for CRT.

title: Rehabilitation in XXXX with radically treated respiratory cancer: A randomised controlled trial comparing two training modalities.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['radical treatment', 'RT']

answer: @entity1 :: (9606,Species) :: ['patients']